Outcome of the meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 to inter-alia approve the completion of second tenure ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's board met on March 27, 2026, and approved two key changes to its board composition. Ms. Gowree Gokhale, a 62-year-old solicitor with 30+ years of legal experience in pharma, IP, and corporate law, has been appointed as an Additional Non-Executive Independent Director for a 5-year term starting April 1, 2026. Ms. Sandra Martyres will complete her second and final term as Independent Director and cease to be a Director from close of business on April 18, 2026. The board has also approved a postal ballot notice to seek shareholder approval for Ms. Gokhale's appointment.
This is a routine board refresh with no impact on operations or financials. Shareholders will get a say via postal ballot on the new independent director's appointment, while Sandra Martyres' exit is a planned end-of-tenure transition.